抗真菌
药品
重症监护医学
医学
抗真菌药
药效学
临床试验
器官移植
抗真菌药
药代动力学
药理学
移植
内科学
皮肤病科
作者
Nicolo Cabrera,Ige George,Adriana M Rauseo,Patrick B Mazi,Andrej Spec
出处
期刊:Current Opinion in Organ Transplantation
[Ovid Technologies (Wolters Kluwer)]
日期:2022-08-01
卷期号:27 (4): 235-242
标识
DOI:10.1097/mot.0000000000000995
摘要
Recipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.These agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.The properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.
科研通智能强力驱动
Strongly Powered by AbleSci AI